Erion JL - Search Results

1

Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.

Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL. Achilefu S, et al. Among authors: erion jl. J Med Chem. 2003 Jul 17;46(15):3403-11. doi: 10.1021/jm030081k. J Med Chem. 2003. PMID: 12852770

2

Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents.

Achilefu S, Jimenez HN, Dorshow RB, Bugaj JE, Webb EG, Wilhelm RR, Rajagopalan R, Johler J, Erion JL. Achilefu S, et al. Among authors: erion jl. J Med Chem. 2002 May 9;45(10):2003-15. doi: 10.1021/jm010519l. J Med Chem. 2002. PMID: 11985468

3

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ. Li WP, et al. Among authors: erion jl. Bioconjug Chem. 2002 Jul-Aug;13(4):721-8. doi: 10.1021/bc015590k. Bioconjug Chem. 2002. PMID: 12121126

4

Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-D-Phe1-octreotide.

Bass LA, Lanahan MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, Anderson CJ. Bass LA, et al. Among authors: erion jl. Bioconjug Chem. 1998 Mar-Apr;9(2):192-200. doi: 10.1021/bc970158h. Bioconjug Chem. 1998. PMID: 9548534

5

Radiotherapeutic efficacy of (153)Sm-CMDTPA-Tyr(3)-octreotate in tumor-bearing rats.

Bugaj JE, Erion JL, Johnson MA, Schmidt MA, Srinivasan A. Bugaj JE, et al. Among authors: erion jl. Nucl Med Biol. 2001 Apr;28(3):327-34. doi: 10.1016/s0969-8051(01)00197-4. Nucl Med Biol. 2001. PMID: 11323245

6

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Lewis JS, et al. Among authors: erion jl. Int J Cancer. 2001 Dec 15;94(6):873-7. doi: 10.1002/ijc.1540. Int J Cancer. 2001. PMID: 11745491 Free article.

7

Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.

Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, Schmidt MA, Bugaj JE. Reubi JC, et al. Eur J Nucl Med. 1998 May;25(5):481-90. doi: 10.1007/s002590050247. Eur J Nucl Med. 1998. PMID: 9575243

8

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt MA, Erion JL, Bugaj JE, Mäcke HR, Krenning EP. de Jong M, et al. Among authors: erion jl. Cancer Res. 1998 Feb 1;58(3):437-41. Cancer Res. 1998. PMID: 9458086

9

Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.

de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, Schmidt MA, Krenning EP, de Jong M. de Visser M, et al. Among authors: erion jl. Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1134-9. doi: 10.1007/s00259-003-1189-y. Epub 2003 May 24. Eur J Nucl Med Mol Imaging. 2003. PMID: 12768332

10

Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jong M. de Visser M, et al. Among authors: erion jl. Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1228-38. doi: 10.1007/s00259-006-0356-3. Epub 2007 Feb 8. Eur J Nucl Med Mol Imaging. 2007. PMID: 17287960 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page